Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
Transpire Bio announced a definitive agreement with Recipharm to develop its TRB-1 and TRB-2 inhaled medicines. These are the first products developed by Transpire Bio and will be indicated for the treatment of asthma and COPD, intended for advanced markets.
Asthma is thought to affect over 300 million people and in 2019 caused 455,000 deaths1. COPD was the third leading cause of death in 2019 with 3.2 million people dying from the condition.2
“Our mission is to improve access to important, life-saving inhaled therapies, and to introduce new inhaled therapies to help address areas of significant unmet medical need”, said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “TRB-1 and TRB-2 are our first offerings in development which will help improve access for potentially millions of patients. We are very excited to be working with Recipharm to advance these important medicines.”
Jean-Francois Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems added: “Recipharm is very pleased to be leveraging its broad experience and expertise in developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products. We look forward to the collaboration.”